R&D | Cutting-edge science and innovative research

News

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

News

Female tennis player goes to serve for the match point

Matchpoint scores $150m for I&I drugs, and other financings

Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.

News

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

R&D

Changing Faces: Pharma and biotech hires, September 2026

There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.

Events

Partner Content

4th RNA-Targeted Drug Discovery Summit - Digital Event

Uniting 150+ RNA Leaders to Progress the RNA Field

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro

R&D

Early detection of cancers will require blood sweat and tear...

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Changing Faces: Pharma and biotech hires, September 2026

There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Digital representation of sepsis bacteria attacking heart

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.